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Abstract
We aimed to evaluate the diagnostic agreement between radiofrequency (RF) intravascular ultrasound (IVUS) and optical 
coherence tomography (OCT) for thin-cap fibroatheroma (TCFA) in non-infarct-related coronary arteries (non-IRA) in 
patients with ST-segment elevation myocardial infarction (STEMI). In the Integrated Biomarker Imaging Study (IBIS-4), 
103 STEMI patients underwent OCT and RF-IVUS imaging of non-IRA after successful primary percutaneous coronary 
intervention and at 13-month follow-up. A coronary lesion was defined as a segment with ≥ 3 consecutive frames (≈1.2 mm) 
with plaque burden ≥ 40% as assessed by grayscale IVUS. RF-IVUS-derived TCFA was defined as a lesion with > 10% 
confluent necrotic core abutting to the lumen in > 10% of the circumference. OCT-TCFA was defined by a minimum cap 
thickness < 65 μm. The two modalities were matched based on anatomical landmarks using a dedicated matching software. 
Using grayscale IVUS, we identified 276 lesions at baseline (N = 146) and follow-up (N = 130). Using RF-IVUS, 208 lesions 
(75.4%) were classified as TCFA. Among them, OCT identified 14 (6.7%) TCFA, 60 (28.8%) thick-cap fibroatheroma 
(ThCFA), and 134 (64.4%) non-fibroatheroma. All OCT-TCFA (n = 14) were confirmed as RF-TCFA. The concordance 
rate between RF-IVUS and OCT for TCFA diagnosis was 29.7%. The reasons for discordance were: OCT-ThCFA (25.8%); 
OCT-fibrous plaque (34.0%); attenuation due to calcium (23.2%); attenuation due to macrophage (10.3%); no significant 
attenuation (6.7%). There was a notable discordance in the diagnostic assessment of TCFA between RF-IVUS and OCT. 
The majority of RF-derived TCFA were not categorized as fibroatheroma using OCT, while all OCT-TCFA were classified 
as TCFA by RF-IVUS.
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Introduction
Acute coronary syndrome is commonly caused by plaque 
rupture which results in luminal thrombosis. Thin-cap 
fibroatheroma (TCFA), a precursor lesion for plaque 
rupture, is characterized by a large necrotic core with 
an overlaying thin fibrous cap [1]. Radiofrequency (RF) 
intravascular ultrasound (IVUS) and optical coherence 
tomography (OCT) represent two intracoronary imaging 
techniques used for in-vivo TCFA detection, although each 
applies distinct methodologies. RF-IVUS involves spectral 
analysis of radiofrequency backscatter data to construct 
tissue maps according to the classification tree and clas-
sify plaque into four major components such as necrotic 
core (NC), dense calcium, fibrous, and fibrofatty tissue 
[2]. RF-TCFA is diagnosed based on the visual assessment 
of these outputs according to the amount and location of 
NC [3]. OCT is an imaging technique using near infrared 
light offering a detailed visual plaque characterization with 
a high-resolution image. Digital images generated using 
the echo time delay of the emitted light and the inten-
sity of the received light are visually assessed to diagnose 
OCT-TCFA based on angle and fibrous cap thickness of 
fibroatheroma (i.e. < 65 μm) [4]. Previous clinical stud-
ies have demonstrated that the presence of TCFA defined 
either by RF-IVUS or OCT was associated with future 
major adverse cardiovascular events [5–8].
Although both techniques have been validated histo-
logically to a certain degree for necrotic core/lipid pool 
[9–11], to date, appropriately sized in vivo imaging studies 
comparing the diagnostic agreement between RF-IVUS 
and OCT for TCFA are lacking. We, therefore, aimed to 
evaluate the diagnostic agreement between RF-IVUS and 
OCT for the assessment of TCFA in non-infarct-related 
coronary arteries (non-IRA) in patients presenting with 
ST-segment elevation myocardial infarction (STEMI).
Methods
The integrated biomarker imaging study (IBIS-4) was a 
prospective cohort study nested into the COMFORTA-
BLE-AMI, which compared biolimus-eluting stents with 
bare metal stents in 1161 STEMI patients undergoing 
primary percutaneous coronary intervention (PCI) at 11 
international centers [12–14]. A total of 103 patients were 
enrolled in the IBIS-4 at five pre-defined centers using 
serial (i.e. baseline and 13 months) RF-IVUS and OCT 
to quantify changes in atherosclerotic plaque character-
istics in non-IRA under long-term high-intensity statin 
therapy (rosuvastatin of 20 mg during the first 2 weeks, 
followed by 40 mg). For the present study, patients not 
available for (1) paired pullbacks (i.e. OCT and RF-IVUS) 
per vessel or (2) matched OCT-analyzed segments with 
IVUS-defined lesions were excluded. All patients provided 
written informed consent and the study was approved by 
the institutional review boards of all participating centers.
Study procedure
The details of image acquisition and analysis methodology 
have been published previously [14, 15]. In brief, follow-
ing successful primary PCI (i.e. TIMI flow ≥ 2), the proxi-
mal 50 mm of two non-infarct related arteries were imaged 
by IVUS, RF-IVUS, and OCT. The region of interest was 
selected between two anatomical landmarks (distal: side-
branch, proximal: LM bifurcation or ostium of the RCA). 
Grayscale IVUS and RF-IVUS images were acquired with a 
20-MHz ultrasound catheter (Eagle Eye, s5, Volcano Coop-
eration, Rancho Cordova, CA) and OCT images with the 
commercially available Fourier-domain C7-XR imaging 
system using the Dragonfly™ imaging catheter (St. Jude 
Medical, St. Paul, MN, USA). Patients were scheduled for 
repeat intracoronary imaging at 13 months.
IVUS and OCT analysis
Definitions of IVUS and OCT variables have been published 
previously [14, 15]. Offline grayscale IVUS and RF-IVUS 
analysis were performed with QIVUS software (Medis, 
Leiden, The Netherlands) at the independent core labora-
tory (Cardialysis, B.V., Rotterdam, The Netherlands). The 
lumen and the external elastic membrane were measured in 
every ≈ 0.4 mm. A lesion was defined as ≥ 3 consecutive 
frames (≈ 1.2 mm) with plaque burden ≥ 40% as assessed by 
grayscale IVUS and considered separate when the distance 
between adjacent lesions was more than 5 mm. RF-IVUS-
derived lesion type including TCFA, thick cap fibroather-
oma (ThCFA), fibrocalcific, fibrotic, and pathological inti-
mal thickening was determined by an independent Corelab 
(Cardialysis, Rotterdam) under the guidance of a senior car-
diologist (H.G.) according to the consensus methodology 
[3]. RF-TCFA was defined as a lesion with > 10% conflu-
ent NC abutting to the lumen in > 10% of the circumference 
in ≥ 3 consecutive frames [3, 16]. Offline OCT analysis was 
performed every 0.4 mm using QCU-CMS V 4.69 (Medis, 
Leiden, The Netherlands) at the Bern University core labo-
ratory. Plaque classification by means of OCT was diag-
nosed by analysts blinded to RF-IVUS (K.Y., R.M., L.R.). 
Fibroatheroma as assessed by OCT was defined as plaque 
with evidence of lipid pool > 90° and no lateral delineation. 
TCFA were defined by a minimum FCT ≤ 65 µm, whereas 
thick-cap fibroatheromas (ThCFA) were fibroatheromas 
with minimum FCT > 65 µm. The principal reasons for the 
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discordance between RF-TCFA and OCT-non-TCFA were 
qualitatively assessed by two analysts (Y.U. and K.Y.) (and 
the third referee [L.R.] in case of disagreement). Pre-defined 
reasons included OCT-ThCFA; OCT-fibrous plaque; attenu-
ation due to calcium; attenuation due to macrophage; no 
significant attenuation. The two modalities were matched 
based on anatomical landmarks using a dedicated match-
ing software (IvusOctRegistration, Version 16, Medis, Lei-
den, The Netherlands). Remodeling index was calculated 
as external elastic membrane (EEM) area of the frame with 
the smallest lumen area within the lesion divided by mean 
EEM area of frames with minimum plaque burden within 
the proximal and distal 5-mm regions adjacent to the lesion 
[17] (Tables 1, 2).
Statistical analysis
Categorical variables are shown as absolute values and per-
centages and were analyzed using Fisher’s exact tests. Con-
tinuous variables are expressed as mean ± standard deviation 
and were analyzed using Student’s t tests. To compare IVUS 
and OCT parameters according to the concordance between 
RF- and OCT-TCFA (Table 3), we ran mixed-effect models 
in which lesion identity nested within patient identity were 
fitted as random intercept to account for the non-independ-
ence of (i) lesions being measured twice (at baseline and 
follow-up) and (ii) lesions originating from the same patient. 
P values were two-tailed and the significance level was set 
to 0.05 in all analyses. Statistical analyses were performed 
using Stata 15 (StataCorp, College Station, TX, USA).
Results
Patient population
Among 103 patients enrolled into IBIS-4, 276 IVUS-defined 
lesions matched with OCT (baseline: 146, follow-up: 130) 
were available in 88 patients/141 vessels (Fig. 1). Patient 
characteristics are summarized in Table 1. Mean age was 
59 ± 10  years, 82% were male, and 13% had diabetes 
mellitus.
Fibroatheroma as assessed by RF‑IVUS and OCT
Table 2 summarizes plaque classifications as assessed by 
RF-IVUS and OCT. Using RF-IVUS, 208 lesions (75.4%) 
were classified as TCFA. Among them, 14 (6.7%) RF-TCFA 
were classified as TCFA by OCT, 60 (28.8%) as ThCFA, 
101 (48.6%) as fibrocalcific, 29 (13.9%) as fibrous, and 4 
Table 1  Patient characteristics
Values are n (%) or mean ± standard deviations
DAPT dual antiplatelet therapy, eGFR estimated glomerular filtration 
rate
Variables N = 88
Age (years) 58.7 ± 10.1
Male sex 81 (82.0%)




Current smoker 36 (40.9%)
Family history of coronary artery disease 25 (29.4%)
Renal failure (eGFR < 60 ml/min/1.73m2) 5 (5.7%)
Previous myocardial infarction 2 (2.3%)





 Any DAPT 87 (100%)
 Statin 87 (100%)
Table 2  Plaque classification as 
assessed by RF-IVUS and OCT
IVUS intravascular ultrasound, OCT optical coherence tomography, PIT pathological intimal thickening, 
TCFA thin-cap fibroatheroma, ThCFA thick-cap fibroatheroma, RF radiofrequency
Lesions (n = 276)
RF-IVUS OCT
TCFA (n = 14) ThCFA 
(n = 77)
Fibrocalcific 






TCFA (n = 208) 14 60 101 29 4
ThCFA (n = 39) 0 12 19 7 1
Fibrocalcific (n = 3) 0 0 3 0 0
Fibrotic (n = 9) 0 2 1 4 2
PIT (n = 17) 0 3 2 7 5
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(1.9%) as normal vessel. All OCT-TCFA (n = 14) were con-
firmed as RF-TCFA (Fig. 2). The concordance rate between 
RF-IVUS and OCT for TCFA diagnosis was 29.7% (RF-
TCFA and OCT-TCFA: 5.1%, RF-non-TCFA and OCT-non-
TCFA: 24.6%). There were 194 lesions (70.3%) classified 
as RF-TCFA but OCT-non-TCFA. The reasons for discord-
ance were: OCT-ThCFA (n = 50, 25.8%); OCT-fibrous 
plaque (n = 66, 34.0%); attenuation due to calcium (n = 45, 
23.2%); attenuation due to macrophage (n = 20, 10.3%); no 
significant attenuation (n = 13, 6.7%) (Fig. 3). The intra- and 
Table 3  IVUS and OCT analysis according to the concordance between RF- and OCT-TCFA
Values are mean ± standard deviations
IVUS intravascular ultrasound, OCT optical coherence tomography, TCFA thin-cap fibroatheroma, RF radiofrequency
RF-TCFA and OCT-
TCFA (n = 14)
RF-TCFA and OCT-non-
TCFA (n = 194)
RF-non-TCFA and OCT-
non-TCFA (n = 68)
P value
IVUS
 Average vessel area  (mm2) 16.4 ± 4.4 17.3 ± 5.6 14.3 ± 4.9 0.273
 Average lumen area  (mm2) 7.1 ± 2.0 8.7 ± 3.0 7.6 ± 2.7 0.018
 Minimum lumen area  (mm2) 4.0 ± 2.0 6.0 ± 2.7 5.9 ± 2.8 0.545
 Percent atheroma volume (%) 56.9 ± 4.7 50.2 ± 6.0 47.0 ± 5.9  < 0.001
 Total atheroma volume  (mm3) 287 ± 120 194 ± 136 107 ± 136 0.001
 Remodeling index 1.23 ± 0.79 1.02 ± 0.31 0.98 ± 0.19 0.001
RF-IVUS
 Percent fibrous area (%) 54.6 ± 7.5 56.7 ± 8.7 64.3 ± 9.7  < 0.001
 Percent fibrofatty area (%) 8.8 ± 5.2 10.3 ± 5.6 13.9 ± 6.4  < 0.001
 Percent necrotic core area (%) 27.1 ± 7.7 23.3 ± 6.5 16.4 ± 7.7  < 0.001
 Percent dense calcium area (%) 9.5 ± 4.4 9.6 ± 6.3 5.4 ± 6.3  < 0.001
OCT
 Average lumen area  (mm2) 6.9 ± 2.6 8.6 ± 3.5 7.7 ± 3.1 0.197
 Minimum lumen area  (mm2) 3.9 ± 2.3 5.9 ± 3.2 6.0 ± 3.4 0.582
 Percent of frames with TCFA (%) 10.3 ± 7.5 0 0  < 0.001
 Percent of frames with ThCFA (%) 46.1 ± 22.0 14.4 ± 27.7 14.0 ± 27.0 0.025
 Percent of frames with fibrous plaque (%) 30.3 ± 20.5 44.6 ± 32.6 44.0 ± 36.4 0.194
 Percent of frames with fibrocalcific plaque (%) 12.9 ± 13.5 33.1 ± 32.5 20.8 ± 31.1 0.373
 Percent of frames with normal vessel (%) 0.5 ± 1.0 7.9 ± 19.0 21.2 ± 34.8 0.134
 Percent of frames with macrophage lines (%) 25.5 ± 17.7 17.6 ± 20.2 10.3 ± 16.3 0.051
 Mean macrophage angle (°) 13.9 ± 16.1 10.6 ± 18.3 5.4 ± 11.5 0.302
Fibroatheroma
 Minimum cap thickness (um) 46.7 (8.9) 133 (77.1) 120 (34.4)  < 0.001
 Mean cap thickness (um) 223 (46.8) 345 (106) 350 (88.1)  < 0.001
 Mean lipid arc (°) 177 (41.8) 133 (38.6) 130 (31.2)  < 0.001
Fig. 1  Patient flow. BL baseline, 
FUP follow-up, IVUS intravas-
cular ultrasound, OCT optical 
coherence tomography, STEMI 
ST-elevation myocardial infarc-
tion, RF radiofrequency
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inter-observer variability were 0.95 and 0.81, respectively. 
To assess the impact of plaque burden on the concordance 
between RF-IVUS and OCT, we evaluated the concordance 
rate among sub-groups stratified according to the mean 
plaque burden of the lesion (Supplementary Table 1). The 
concordance rate for TCFA diagnosis was 31.2% (RF-TCFA 
and OCT-TCFA: 0.7%, RF-non-TCFA and OCT-non-TCFA: 
30.4%) in lesions with mean plaque burden ≥ 40% and < 50% 
(n = 138), and 24.6% (RF-TCFA and OCT-TCFA: 10.3%, 
RF-non-TCFA and OCT-non-TCFA: 14.3%) in lesions with 
Fig. 2  Representative case of 
TCFA determined by RF-IVUS 
and OCT
Fig. 3  Principal reasons for 
discordance between RF-IVUS 
and OCT. IVUS intravascu-
lar ultrasound, OCT optical 
coherence tomography, TCFA 
thin-cap fibroatheroma, ThCFA 
thick-cap fibroatheroma, RF 
radiofrequency
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mean plaque burden ≥ 50% (n = 126). When applying the 
definition of OCT-TCFA with minimum FCT < 75 μm, the 
concordance rate between RF-IVUS and OCT for TCFA 
diagnosis increased to 34.4% (RF-TCFA and OCT-TCFA: 
9.8%, RF-non-TCFA and OCT-non-TCFA: 24.6%) (Supple-
mentary Table 2).
Distribution of minimal fibrous cap thickness 
of OCT‑FA among RF‑TCFA
Figure 4 summarizes the distribution of minimal FCT of 
OCT-FA among RF-TCFA lesions. FCT ranged from 23 
to 473 µm, with a median of 86 µm (interquartile range 
65 µm). Among 74 RF-TCFA with OCT-FA morphology, 
18.9% had minimum FCT ≤ 65 µm and 50.0% had minimum 
FCT ≤ 85 µm by OCT.
IVUS and OCT analysis according to the concordance 
between RF‑ and OCT‑TCFA
Table 3 summarizes quantitative IVUS and OCT analysis 
according to the concordance between RF- and OCT-TCFA. 
Lesions with RF- and OCT-TCFA had smaller minimum 
lumen area, greater percent atheroma volume, greater 
remodeling index, and greater percent necrotic core area 
compared with other groups.
Discussion
The major findings of the present study were (1) there 
was a substantial discordance (70.3%) in the assessment 
of TCFA between RF-IVUS and OCT. The vast majority 
of RF-TCFA were not categorized as TCFA by OCT, while 
all OCT-TCFA were classified as TCFA by RF-IVUS, and 
(2) the reasons for discordance between RF-TCFA and 
OCT-non-TCFA were OCT-fibrous plaque (34%), OCT-
ThCFA (26%), attenuation due to calcium (23%), attenu-
ation due to macrophage accumulations (10%), and no 
significant attenuation (7%).
Although previous ex-vivo studies have demonstrated 
that both RF-IVUS and OCT had a good diagnostic accu-
racy (76−98%) for TCFA compared with histology [9, 
18, 19], there is limited data on the direct comparison 
of TCFA detection between RF-IVUS and OCT. Previous 
in-vivo imaging studies have reported a lower discordance 
rate between RF-IVUS and OCT for in-vivo TCFA iden-
tification (≈ 20–30%) compared with the present study; 
however, underlying reasons for the discrepancy remain 
poorly understood [20, 21].
There are several explanations for the disagreement 
between RF-IVUS and OCT for the diagnosis of TCFA. 
First, the commonly acknowledged cut-off of fibrous cap 
thickness threshold to define TCFA is 65 µm, which is 
below the resolution of IVUS (100–150 µm). Unlike OCT, 
RF-IVUS defines TCFA as “ > 10% confluent NC abutting 
to the lumen for > 30° in ≥ 3 consecutive frames” with-
out consideration of cap thickness, which was based on 
the consensus among experts rather than the result of an 
autopsy validation study [3]. This inherent limitation of 
RF-IVUS may result in an overestimation of the incidence 
of TCFA as observed in the current study. OCT is consid-
ered the gold standard diagnostic tool to correctly measure 
the fibrous cap thickness in vivo; as reportedly shown in 
a previous histology study suggesting a good correlation 
of the fibrous cap thickness between OCT and histology 
(r = 0.90, P < 0.001) [22].
Since the definition of RF-TCFA entirely depends on 
the amount and location of NC displayed by the deci-
sion algorithm, an overestimation of necrotic core by 
RF-IVUS may have resulted in a notable false-positive 
rate of RF-TCFA identification compared with OCT. A 
previous study comparing histology with RF-IVUS and 
OCT showed that the misclassification of necrotic core 
was commonly encountered in the region of calcifications, 
in which the adjacent plaque composition is incorrectly 
categorized as NC [18]. The misclassification is poten-
tially related to calcium being included in the algorithm 
for the detection of necrotic core [2]. In our study, this 
was the case in 23% of RF-IVUS TCFA lesions. Although 
Fig. 4  Distribution of minimal fibrous cap thickness of OCT-FA 
lesions among RF-TCFA lesions (n = 74). FA fibroatheroma, OCT 
optical coherence tomography, TCFA thin-cap fibroatheroma, RF 
radiofrequency
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the detection of necrotic core behind a superficial calcific 
pool might be impossible by OCT [23], such a plaque by 
definition does not fulfill the definition of a TCFA (i.e. 
thin fibrous cap overlying necrotic core). With regards to 
fibrous plaques, an ex-vivo animal study comparing RF-
IVUS vs. histology reported that dense fibrous tissue was 
falsely categorized as necrotic core [24]. In accordance 
with this data, our study revealed that 34% of plaques with 
a fibrous morphology by OCT were categorized as TCFA 
by RF-IVUS.
Some technical aspects of RF-IVUS also deserve consid-
eration. First, RF-IVUS catheters used in the IBIS-4 study 
(i.e. s5) may overestimate the amount of NC compared with 
its precursor (i.e. in-vision gold). Second, the correct diag-
nosis of RF-TCFA especially in cross-sections with mod-
erate plaque burden might be more challenging, although 
a sensitivity analysis did not show a relevant difference in 
the concordance rate as a function of plaque burden (Sup-
plementary Table 1). Of note, and in line with our findings, 
a higher prevalence of RF-TCFA has been reported in clini-
cal studies investigating non-flow-limiting lesions (21.6% 
in PROSPECT [5], 41% in HORIZON AMI [25], 37.4% 
in ATHEROREMO-IVUS [6], 61.6% in VIVA [7]) com-
pared with the OCT-TCFA (18% in Tian et al. [26], 15.6% 
in IBIS-4 [27], 7.3% in Tanaka et al. [28]) and histology-
defined TCFA of 10.8% [29], suggesting a relatively consist-
ent overestimation in TCFA diagnosis by RF-IVUS in the 
literature. Furthermore, the GLAGOV RF-IVUS sub-anal-
ysis has recently demonstrated that RF-IVUS was unable 
to detect the significant regression in necrotic core between 
the evolocumab and placebo groups (Δ 76 weeks—baseline: 
− 0.6 ± 0.5  mm3 vs. − 0.1 ± 0.5  mm3, P = 0.49) despite the 
significant atheroma regression in the evolocumab group, 
questioning the utility of RF-IVUS in assessing the effects 
of antiatherosclerotic therapies [30].
Although all OCT-TFCA were confirmed as TCFA by 
RF-IVUS in the current study, the presence of macrophages, 
calcifications, and artefacts render TCFA diagnosis by OCT 
challenging as suggested by several ex vivo studies [31, 32]. 
A previous OCT study demonstrated that standardization of 
in-vivo FCT assessment by OCT and development of image 
interpretation criteria resulted in significantly higher levels 
of interobserver variability of FCT measurement [33].
From a clinical perspective, the PROSPECT and VIVA 
have demonstrated that RF-TCFA was associated with sub-
sequent major adverse events [5, 7]. Given the overestima-
tion of RF-TCFA compared with OCT-TCFA as shown in 
the present study, the prognostic value of RF-TCFA shown 
in the PROSPECT and VIVA appeared due to the amount 
of NC and co-existing other features such as plaque burden 
and lumen area rather than fibrous cap thickness itself. At 
variance with the PROSPECT and VIVA, in the ATHER-
OREMO-IVUS study, the presence of RF-TCFA with a 
plaque burden ≥ 70% was significantly associated with 
MACE (cumulative MACE incidence when present: 37.7% 
vs. 24.6% when absent; adjusted HR: 1.73; 95% CI 1.12 
to 2.66; P = 0.013), while the presence of a TCFA lesion 
alone was not independently associated with MACE [34]. 
Although differences in study design across trials need to 
be considered, an incremental value of RF-derived plaque 
characterization over grayscale IVUS (i.e. plaque burden 
assessment) remained uncertain. The prognostic significance 
of OCT-TCFA has been demonstrated in a few prospective 
studies (the CLIMA [35] and the COMBINE OCT-FFR 
study [36]). Direct comparison of the prognostic signifi-
cance between RF- vs. OCT-TCFA is not available to date. 
Near-infrared spectroscopy (NIRS) has recently become 
available as an alternative method to identify the extent of 
lipid-rich plaque in the coronary arteries. The LRP study and 
PROSPECT II study have reported that lipid core burden 
index as assessed by NIRS was significantly associated with 
future MACE [37]. Since RF-IVUS is no longer used in the 
daily practice, OCT and NIRS are the preferred methods to 
detect the vulnerable plaque, although no adequately pow-
ered prospective randomized trials assessing the impact of 
vulnerable plaque detection by intracoronary imaging on the 
subsequent treatment strategy have been conducted to date.
Limitations
Several limitations should be considered in the present study. 
First, only STEMI patients were enrolled in the IBIS-4 study, 
which may limit the generalizability of the findings to other 
patient subsets (i.e. chronic coronary syndrome). Second, 
although matching between RF-IVUS and OCT was per-
formed using a dedicated matching software by expert ana-
lysts, small longitudinal mismatches may affect the findings 
of the current study. Third, the findings of the current study 
do not apply to other radiofrequency analysis methods for 
plaque classification. Fourth, although the current study 
provides the important insights for better understanding of 
vulnerable plaque features defined by RF-IVUS and OCT, 
the clinical significance of the current study may be limited 
since RF-IVUS is no longer used in the daily practice.
Conclusions
There was a notable discordance in the diagnostic assess-
ment of TCFA between RF-IVUS and OCT. The majority 
of RF-IVUS derived TCFA were not categorized as fibroath-
eroma using OCT, while all OCT derived TCFA were clas-
sified as fibroatheroma by RF-IVUS.
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